Compare JRI & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JRI | HUMA |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | 184 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.3M | 308.6M |
| IPO Year | N/A | N/A |
| Metric | JRI | HUMA |
|---|---|---|
| Price | $12.66 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.19 |
| AVG Volume (30 Days) | 141.4K | ★ 8.7M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 9.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $444.16 |
| Revenue Next Year | N/A | $248.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.67 | $0.55 |
| 52 Week High | $14.37 | $2.84 |
| Indicator | JRI | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 35.21 |
| Support Level | $12.42 | $0.60 |
| Resistance Level | $13.20 | $1.28 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 47.41 | 0.07 |
Nuveen Real Asset Income and Growth Fund is a closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.